Forendo Pharma signs important deal with Novartis

11 December 2019

Forendo Pharma, a Finland-based clinical-stage drug development portfolio company of Karolinska Development (Nasdaq OMX: KDEV), today announced the signing of a license and collaboration agreement with Swiss pharma giant Novartis (NOVN: VX).

The joint research collaboration is aimed at the identification of novel drugs for the treatment of chronic liver diseases. Novartis receives a worldwide exclusive license to drug candidates generated under the collaboration.

Forendo says it has world leading experience in drug discovery and development of inhibitors of the HSD17B (17-beta-hydroxysteroid dehydregonase) enzyme family. These enzymes demonstrate significant potential in multiple disease areas beyond Forendo's own women's health focused programs. This is a diverse family of enzymes that regulate hormone action in specific tissues and where Forendo, together with its' close academic collaborators, has its core competence and leading experience. Forendo's lead program, HSD17B1 inhibitor FOR-6219, targeted for endometriosis, is in Phase Ib clinical studies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK